Law Offices of Howard G. Smith Announces Investigation of Palomar Medical Technologies Inc.
March 19, 2013 1:20 PM ET
Law Offices of Howard G. Smith announces that it is investigating potential claims against the Board of Directors of Palomar Medical Technologies Inc. (“Palomar Medical” or the “Company”) PMTI related to the proposed acquisition of the Company by Cynosure Inc. Under the terms of the transaction, valued at approximately $294 million, shareholders will receive $6.825 in cash and $6.825 in Cynosure common stock for each share of Palomar Medical share they own.
This investigation concerns the Board of Directors’ process for consideration of the proposed acquisition, and whether Palomar Medical is acting in its shareholders’ best interests. The Company has seen substantial recent growth. Its share price has skyrocketed from $7.18 on November 14, 2012 to $12.62 on March 15, 2013. Further, at least one analyst has set a target price for the Company’s stock at $14.50 per share.
If you are a shareholder of Palomar Medical, if you have information or would like to learn more about our investigation, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to email@example.com, or visit our website at http://www.howardsmithlaw.com.
Copyright 2013 Business Wire
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.